Operationalizing hippocampal volume as an enrichment biomarker for amnestic mild cognitive impairment trials: effect of algorithm, test-retest variability, and cut point on trial cost, duration, and sample size-Reference-Cited by-同舟云学术

Operationalizing hippocampal volume as an enrichment biomarker for amnestic mild cognitive impairment trials: effect of algorithm, test-retest variability, and cut point on trial cost, duration, and sample size

Published:2014-04 Issue:4 Volume:35 Page:808-818
ISSN:0197-4580
Container-title:Neurobiology of Aging
language:en
Short-container-title:Neurobiology of Aging

Author:

Yu Peng,Sun Jia,Wolz Robin,Stephenson Diane,Brewer James,Fox Nick C.,Cole Patricia E.,Jack Clifford R.,Hill Derek L.G.,Schwarz Adam J.

Funder

U.S. Food and Drug Administration

Science Foundation Arizona

National Institutes of Health

National Institute on Aging

National Institute of Biomedical Imaging and Bioengineering

Publisher

Elsevier BV

Subject

Geriatrics and Gerontology,Developmental Biology,Neurology (clinical),Aging,General Neuroscience

Reference32 articles.

1. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease;Albert;Alzheimers Dement.,2011

2. Targeted recruitment using cerebrospinal fluid biomarkers: implications for Alzheimer's disease therapeutic trials;Barnes;J. Alzheimers Dis.,2013

3. Determining cut-points for Alzheimer's disease biomarkers: statistical issues, methods and challenges;Bartlett;Biomark. Med.,2012

4. Survey of protocols for the manual segmentation of the hippocampus: preparatory steps towards a joint EADC-ADNI harmonized protocol;Boccardi;J. Alzheimers Dis.,2011

5. Neuropathological staging of Alzheimer-related changes;Braak;Acta. Neuropathol.,1991

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. 15 Years of Longitudinal Genetic, Clinical, Cognitive, Imaging, and Biochemical Measures in DIAN;2024-08-09

2. Integrating the Patient’s Voice into the Research Agenda for Treatment of Chemosensory Disorders;Chemical Senses;2024-05-18

3. Noninvasive Magnetic Resonance Imaging Measures of Glymphatic System Activity;Journal of Magnetic Resonance Imaging;2023-09

4. FDA-approved machine learning algorithms in neuroradiology: A systematic review of the current evidence for approval;Artificial Intelligence in Medicine;2023-09

5. Updated Review of the Evidence Supporting the Medical and Legal Use of NeuroQuant® and NeuroGage® in Patients With Traumatic Brain Injury;Frontiers in Human Neuroscience;2022-04-08